Adults with B cell-precursor acute lymphoblastic leukaemia (BCP-ALL) negative for minimal residual disease (MRD) after induction chemotherapy have a superior prognosis relative to those with MRD⁺ status, although many will eventually have disease relapse. Now, data from the phase III E1910 trial demonstrate that addition of the CD19 × CD3 bispecific T cell engager blinatumomab to consolidation chemotherapy improves overall survival (OS) in this setting.

Patients received standard-of-care induction chemotherapy. Those with an MRD^– complete response (<0.01% leukaemic cells in bone marrow; 224 of 488 patients) were randomly allocated (1:1) to receive standard-of-care consolidation chemotherapy with or without blinatumomab, followed by standard maintenance therapy in both groups. OS in patients with MRD^– disease was the primary end point.

诱导化疗后微小残留病 (MRD) 阴性的 B 细胞前体急性淋巴细胞白血病 (BCP-ALL) 成人相对于 MRD ⁺状态的患者来说预后较好，尽管许多人最终会出现疾病复发。现在，来自 III 期 E1910 试验的数据表明，在巩固化疗中添加 CD19 × CD3 双特异性 T 细胞接合剂 blinatumomab 可改善这种情况下的总生存期 (OS)。

患者接受标准护理诱导化疗。具有 MRD ^–完全缓解（骨髓中白血病细胞<0.01%；488 名患者中的 224 名）的患者被随机分配 (1:1) 接受标准护理巩固化疗（含或不含博纳吐单抗），然后进行标准维持治疗两组均进行治疗。 ^MRD疾病患者的 OS 是主要终点。